Few Washington insiders doubt that a bill that allows terminally ill patients to circumvent FDA as they pursue Hail Mary pass therapies will become the law of the land.
In his new book, “No More Tears: The Dark Secrets of Johnson & Johnson,” Gardiner Harris, who was previously the public health and pharmaceutical business reporter for The New York Times, talks about the history of the overuse of red blood cell growth factors in oncology.
